CM Life Sciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eli Decatur Casdin
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 667 Madison Avenue New York City NY United States of America
- IPO Date
- Oct 26, 2020
- CIK
- 0001818331
- Website
- i.cmlifesciencesspac.com
- Similar Companies
- Business
- CM Life Sciences, Inc. (CMLF) is a blank check company, or special purpose acquisition company (SPAC), sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP that seeks to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more life sciences companies, focusing on life sciences tools, synthetic biology, diagnostics, and ecosystem services supporting drug discovery, development, and manufacturing; it targets operationally focused entities with regulated products and high-value R&D tools for academia, government, and industry. Founded in 2020 and headquartered in New York, New York, the company went public in October 2020 through an initial public offering that raised approximately $442.75 million, which it holds in trust pending a business combination; it operates without significant current operations and emphasizes a buy-and-build strategy for fragmented life sciences sectors. In 2021, CM Life Sciences, Inc. completed a definitive business combination with Sema4 (now operating as GeneDx Holdings Corp.), a genomics and health intelligence company providing AI-driven genomic and clinical data platforms, exome/genome sequencing for rare diseases, and pediatric diagnostics, delisting under CMLF and relaunching the combined entity under new tickers (SMFR then WGS); subsequent developments include Sema4's acquisition of GeneDx assets from OPKO Health and Mount Sinai Genomics, Inc.'s acquisition of CM Life Sciences, Inc. from its sponsors, reflecting ongoing restructuring in the post-SPAC life sciences landscape as of 2025.
CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination
3 Stocks Cathie Wood Keeps Buying
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
Cathie Wood's ARK Invest Buys Over 330,000 Shares of CM Life Sciences
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance
CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten Investors
CM Life Sciences: SPAC Acquires Sema4, A Promising AI Health Intelligence Co.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of CM Life Sciences, Inc. - CMLF
CMLF Stock Price Increases Over 80% Over The Past Week: Why It Happened
CMLF Stock Price Hit A Day High Of Over 65.9%: Why It Happened